Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION
Completed
- Conditions
- Hypercholesterolemia
- Registration Number
- NCT00526721
- Lead Sponsor
- AstraZeneca
- Brief Summary
To evaluate achievement ratio of treatment target goal in hypercholesterolemia patients with high risk after high dose rosuvastatin(20mg/day) titration
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1482
Inclusion Criteria
-
High-risk hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on the physician's clinical decision and fulfill the following criteria
- Over 18 years of age
- Have history of CHD or CHD risk equivalents, such as peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease (TIA or stroke of carotid origin or >50% obstruction of carotid artery), DM, and 2+ risk factors with 10-year risk CHD>20%
Read More
Exclusion Criteria
- Patients already taking other hyperlipidemic agents
- Patients who do not fulfil the indication criteria for statin therapy
- Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇰🇷Seoul, Songpa-gu, Korea, Republic of